Biden Has Completed Radiation for Cancer
Digest more
A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer, researchers found in a clinical trial.
The Brighterside of News on MSN
New drug combo cuts risk of death for men with prostate cancer by 40%
Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive global trial has found that a combination of two medications, enzalutamide and leuprolide,
Targeting prostate-specific membrane antigen, Lu-PSMA-617 has demonstrated clinical benefits in patients with PSMA-positive mCRPC after progression on ARPIs, including patients with and without prior taxane treatment. PSMA-Add was the first phase III trial to target PSMA in mHSPC.